iCardio.ai Joins Forces with SARC MedIQ to Enhance Cardiovascular Imaging Through AI Technology
iCardio.ai teams up with SARC MedIQ to enhance ultrasound interpretation using cutting-edge AI technology.


iCardio.ai has announced an exciting partnership with SARC
MedIQ to enhance ultrasound image interpretation through advanced AI tools. By
integrating iCardio.ai’s innovative AI technology into SARC MedIQ’s picture
archiving and communication system (PACS), the collaboration aims to
significantly improve the speed, accuracy, and efficiency of ultrasound
diagnostics, particularly in cardiology.
Joseph Sokol, CEO of iCardio.ai, expressed enthusiasm about
the partnership, noting, “SARC MedIQ's leadership is visionary, and their
alignment with our mission makes them an ideal partner. AI is transforming
medicine, and collaborations like this are propelling that shift forward. Our
technology will empower clinicians and streamline the patient journey for
better outcomes.”
This integration will make AI tools more accessible to
clinicians, potentially transforming the diagnostic landscape for
echocardiography by introducing new efficiencies. SARC MedIQ CEO Asaad Hakeem
shared, “Incorporating iCardio.ai’s automated AI into our PACS system marks a
significant step toward providing our users with enhanced tools for evaluating
and diagnosing cardiovascular conditions."
Earlier this year, iCardio.ai partnered with Viz.ai to
advance the rapid detection of aortic stenosis. iCardio.ai is dedicated to
developing machine learning and deep learning algorithms for ultrasound
analysis, while SARC MedIQ provides advanced, affordable healthcare solutions
across Asia, North America, Africa, and Australia.

My international experience as a researcher in Taiwan for three years has equipped me with a global perspective, enabling me to create content that resonates with an international audience.
Plus dans Pharma News
Tous les articles →
Ab Science révise les calendriers d'essais après trois inspections GCP

Novo Nordisk signe un accord de 2,6 milliards $ avec Hengrui pour un GLP-1 oral

Discussion